Antitumor profiles and cardiac electrophysiological effects of aurora kinase inhibitor ZM447439

• 발행기관: 대한생리학회-대한약리학회
• 저자명: Hyang-Ae Lee Miso Kwon Hyeon-A Kim Ki-Suk Kim
• 간행물 정보: 『The Korean Journal of Physiology & Pharmacology』제23권 제5호, 393~402쪽, 전체 10쪽
• 주제분류: 의약학 > 의학일반
• 파일형태: PDF
• 발행일자: 2019.09.30

영문 초록

Aurora kinases inhibitors, including ZM447439 (ZM), which suppress cell division, have attracted a great deal of attention as potential novel anti-cancer drugs. Several recent studies have confirmed the anti-cancer effects of ZM in various cancer cell lines. However, there have been no studies regarding the cardiac safety of this agent. We performed several cytotoxicity, invasion and migration assays to examine the anti-cancer effects of ZM. To evaluate the potential effects of ZM on cardiac repolarisation, whole-cell patch-clamp experiments were performed with human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and cells with heterogeneous cardiac ion channel expression. We also conducted a contractility assay with rat ventricular myocytes to determine the effects of ZM on myocardial contraction and/or relaxation. In tests to determine in vitro efficacy, ZM inhibited the proliferation of A549, H1299 (lung cancer), MCF-7 (breast cancer) and HepG2 (hepatoma) cell lines with IC50 in the submicromolar range, and attenuated the invasive and metastatic capacity of A549 cells. In cardiac toxicity testing, ZM did not significantly affect I Na, I Ks or I K1, but decreased I hERG in a dose-dependent manner (IC50: 6.53 μM). In action potential (AP) assay using hiPSC-CMs, ZM did not induce any changes in AP parameters up to 3 μM, but it at 10 M induced prolongation of AP duration. In summary, ZM showed potent broad-spectrum anti-tumor activity, but relatively low levels of cardiac side effects compared to the effective doses to tumor. Therefore, ZM has a potential to be a candidate as an anti-cancer with low cardiac toxicity.

목차

INTRODUCTION

METHODS

RESULTS

DISCUSSION

키워드

Anticancer agents Aurora kinases inhibitor Cardiotoxicity Efficacy testing ZM447439